Given the high prevalence of p53 mutations in cancer, there has been significant interest in developing therapies that can restore normal p53 function or mimic its activity. Approaches being explored include gene therapy to introduce a functional copy of the p53 gene, small molecules that can reactivate mutant p53, and drugs that target pathways regulated by p53. However, these therapies are still largely in the experimental stage.
